These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

770 related items for PubMed ID: 30118353

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Tofacitinib: A Review in Psoriatic Arthritis.
    Paik J, Deeks ED.
    Drugs; 2019 Apr; 79(6):655-663. PubMed ID: 30895473
    [Abstract] [Full Text] [Related]

  • 5. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
    Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, Kudlacz E, Wang C, Menon S, Hendrikx T, Kanik KS.
    N Engl J Med; 2017 Oct 19; 377(16):1525-1536. PubMed ID: 29045207
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.
    Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F, Cieślak D, Graham D, Wang C, Menon S, Hendrikx T, Kanik KS.
    N Engl J Med; 2017 Oct 19; 377(16):1537-1550. PubMed ID: 29045212
    [Abstract] [Full Text] [Related]

  • 8. Tofacitinib for the treatment of psoriasis and psoriatic arthritis.
    Ighani A, Georgakopoulos JR, Yeung J.
    G Ital Dermatol Venereol; 2020 Aug 19; 155(4):400-410. PubMed ID: 32348084
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Novel Oral Therapies for Psoriasis and Psoriatic Arthritis.
    Yiu ZZ, Warren RB.
    Am J Clin Dermatol; 2016 Jun 19; 17(3):191-200. PubMed ID: 26923915
    [Abstract] [Full Text] [Related]

  • 13. Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.
    Vyas D, O'Dell KM, Bandy JL, Boyce EG.
    Ann Pharmacother; 2013 Nov 19; 47(11):1524-31. PubMed ID: 24285764
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Tofacitinib in the Treatment of Rheumatoid Arthritis and Chronic Plaque Psoriasis.
    Gupta AK, Cernea M, Lynde CW.
    Skin Therapy Lett; 2017 Mar 19; 22(2):1-7. PubMed ID: 28329404
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Targeting the Janus kinases in rheumatoid arthritis: focus on tofacitinib.
    Yamaoka K, Tanaka Y.
    Expert Opin Pharmacother; 2014 Jan 19; 15(1):103-13. PubMed ID: 24188100
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.